Core Insights - Lexeo Therapeutics, Inc. has appointed Dr. Kyle Rasbach as Chief Financial Officer, effective immediately, bringing extensive life sciences experience to the company [1][2] - The appointment comes at a crucial time as the company is advancing its pipeline and preparing for pivotal studies in gene therapy programs [2][3] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company focused on developing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease [4] - The company employs a stepwise development approach, utilizing early proof-of-concept functional and biomarker data to progress its pipeline [4] Leadership Background - Dr. Rasbach has a strong background in life sciences, having previously served as Chief Business Officer at Zentalis Pharmaceuticals and as a Portfolio Manager for Eventide Asset Management's 1.8 billion healthcare & life sciences fund [2] - His experience includes managing over 40 billion in pharmaceutical, specialty pharmaceutical, and biotechnology investments at T. Rowe Price [2][3] - Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences, a PharmD, and an MBA, enhancing his capability to contribute to Lexeo's growth [3]
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer